| Literature DB >> 25501426 |
Christoffer Laustsen1, Kasper Lipsø2, Jakob Appel Ostergaard3, Rikke Nørregaard4, Allan Flyvbjerg3, Michael Pedersen5, Fredrik Palm6, Jan Henrik Ardenkjær-Larsen7.
Abstract
Good glycemic control is crucial to prevent the onset and progression of late diabetic complications, but insulin treatment often fails to achieve normalization of glycemic control to the level seen in healthy controls. In fact, recent experimental studies indicate that insufficient treatment with insulin, resulting in poor glycemic control, has an additional effect on progression of late diabetic complications, than poor glycemic control on its own. We therefore compared renal metabolic alterations during conditions of poor glycemic control with and without suboptimal insulin administration, which did not restore glycemic control, to streptozotocin (STZ)-diabetic rats using noninvasive hyperpolarized (13)C-pyruvate magnetic resonance imaging (MRI) and blood oxygenation level-dependent (BOLD) (1)H-MRI to determine renal metabolic flux and oxygen availability, respectively. Suboptimal insulin administration increased pyruvate utilization and metabolic flux via both anaerobic and aerobic pathways in diabetic rats even though insulin did not affect kidney oxygen availability, HbA1c, or oxidative stress. These results imply direct effects of insulin in the regulation of cellular substrate utilization and metabolic fluxes during conditions of poor glycemic control. The study demonstrates that poor glycemic control in combination with suboptimal insulin administration accelerates metabolic alterations by increasing both anaerobic and aerobic metabolism resulting in increased utilization of energy substrates. The results demonstrate the importance of tight glycemic control in insulinopenic diabetes, and that insulin, when administered insufficiently, adds an additional burden on top of poor glycemic control.Entities:
Keywords: Hyperpolarization; kidney; magnetic resonance imaging; renal metabolism; type 1 diabetes
Year: 2014 PMID: 25501426 PMCID: PMC4332212 DOI: 10.14814/phy2.12233
Source DB: PubMed Journal: Physiol Rep ISSN: 2051-817X
Changes in body weight, kidney weight, blood glucose, and the levels of plasma creatinine, urea, and electrolytes after insulin treatment.
| BW g | KW g | Blgl mmol/L | HbA1c % | Crea | Urea mmol/L | Osm mOsm | Na+ mmol/L | K+ mmol/L | |
|---|---|---|---|---|---|---|---|---|---|
| DM | 216±14 | 1.1±0.1 | 28.6±1.6 | 11.0±1.1 | 23±4 | 12±2 | 347±34 | 149±15 | 4.5±1.0 |
| DM + I | 220±9 | 1.1±0.1 | 18.3±2.6 | 10.3±0.9 | 20±4 | 9±3 | 306±62 | 138±33 | 4.2±0.9 |
BW, body weight; KW, kidney weight; Blgl, blood glucose, prior scan; HbA1c, hemoglobin A1c; Crea, plasma creatinine; Osm, plasma osmolality; Na+, plasma sodium, K+, plasma potassium.
Mean±SEM of n = 6/group.
Denotes P < 0.05 versus untreated group.
Markers of oxidative stress damage.
| TBARS | Protein carbonyls | |||
|---|---|---|---|---|
| Plasma nmol/L | Kidney cortex nmol/g | Plasma nmol/L | Kidney cortex | |
| DM | 8.84±0.13 | 1.70±0.14 | 17.0±2.6 | 2.8±1.5 |
| DM + I | 8.50±0.07 | 1.30±0.14 | 16.9±2.7 | 2.2±0.3 |
TBARS, thiobarbituric acid reactive substances.
Mean±SEM of n = 6/group.
Denotes P < 0.05 versus untreated group.
Figure 1.Diagram of the metabolic pathways observed in the hyperpolarized [1‐13C]pyruvate experiment.
Figure 2.Metabolic parameters. Pyruvate‐to‐total‐carbon (A), lactate‐to‐pyruvate (B), Lactate‐to‐total‐carbon (C), alanine‐to‐pyruvate (D), Alanine‐to‐total‐carbon (E) bicarbonate‐to‐pyruvate (F) and bicarbonate‐to‐total‐carbon (G) ratios and representative images of kidneys from diabetic rats with (DM + I) and without suboptimal insulin treatments (DM). *denotes P < 0.05 versus untreated diabetes.
Figure 3.Lactate‐to‐bicarbonate (A), lactate‐to‐alanine (B), and alanine‐to‐bicarbonate (C) ratios and representative images of kidneys from diabetic rats with (DM + I) and without (DM) suboptimal insulin treatments. *denotes P < 0.05 versus untreated diabetes.
Figure 4.Kidney cortex and medulla R2* values in diabetic rats with and without suboptimal insulin treatments.